Last 12 months
Inside the activity.
11 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 8 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2022 Filed Nov 10, 2022 23:32 UTC |
HALLQUIST CONSTANCE J.Director
|
PurchaseCommon Stock | 10.537 | $106.93 | $1,126.72 |
DisclosureSEC source: 0001628280-22-029560 · wf-form4_166812310986073.xml · nonDerivative · entry 1 HALLQUIST CONSTANCE J. · CIK 0001645615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,892.561 F1 · shares: The shares were acquired pursuant to a dividend reinvestment feature in connection with deferred units held by the Reporting Person pursuant to the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). The shares accrued when and as dividends were paid on Medifast common stock. Read SEC document |
| November 08, 2022 Filed Feb 10, 2023 02:06 UTC |
Xian MingDirector
|
GrantRestricted Stock Units (cash settled) · Derivative | 9.7766 | $106.93 | $1,045.41 |
DisclosureSEC source: 0001628280-23-003055 · wf-form4_167599477045468.xml · derivative · entry 1 Xian Ming · CIK 0001743879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,964.222 Underlying: Common Stock · 9.7766 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (cash settled) is the economic equivalent of one share of Medifast's common stock. Restricted stock units become payable, in cash, following termination of the Reporting Person's service as a director. F2 · kind: Accrual of dividend equivalents in connection with deferred units held by the Reporting Person pursuant to the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). The dividend equivalents accrued when and as dividends were paid on Medifast common stock. F1 · derivative.exercise_date: Each restricted stock unit (cash settled) is the economic equivalent of one share of Medifast's common stock. Restricted stock units become payable, in cash, following termination of the Reporting Person's service as a director. F1 · derivative.expiration_date: Each restricted stock unit (cash settled) is the economic equivalent of one share of Medifast's common stock. Restricted stock units become payable, in cash, following termination of the Reporting Person's service as a director. Read SEC document |
| November 04, 2022 Filed Nov 10, 2022 23:33 UTC |
BROWN JEFFREY JDirector
|
PurchaseCommon Stock | 560.972 | $105.06 | $58,935.72 |
DisclosureSEC source: 0001628280-22-029564 · wf-form4_166812321065156.xml · nonDerivative · entry 2 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Brown Equity Partners, LLC Disclosed balance after: 36,498.822 F2 · kind: The shares were acquired by Brown Equity Partners, LLC, for which the reporting person is the managing member, pursuant to a broker-sponsored Dividend Reinvestment Plan. F3 · ownership.nature: These shares are directly owned by Brown Equity Partners, LLC, for which the reporting persons is the managing member. Read SEC document |
| September 13, 2022 Filed Feb 10, 2023 02:07 UTC |
MacKenzie Jonathan BarrettVP, Finance & CAO
|
Tax withholdingCommon Stock | 10 | $124.56 | $1,245.60 |
DisclosureSEC source: 0001628280-23-003056 · wf-form4_167599481548690.xml · nonDerivative · entry 1 MacKenzie Jonathan Barrett · CIK 0001883230 · VP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 647 Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 21:00 UTC |
BROWN JEFFREY JDirector
|
PurchaseCommon Stock | 3,530 | $126.63 | $447,003.90 |
DisclosureSEC source: 0001104659-22-089416 · tm2223244-1_4seq1.xml · nonDerivative · entry 4 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Jeffrey Brown Living Trust Disclosed balance after: 3,940 F3 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $126.11 to $126.96, inclusive. F4 · ownership.nature: These shares are directly owned by Jeffrey Brown Living Trust, for which the reporting person is the sole trustee and sole beneficiary. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 21:00 UTC |
BROWN JEFFREY JDirector
|
PurchaseCommon Stock | 410 | $125.72 | $51,545.20 |
DisclosureSEC source: 0001104659-22-089416 · tm2223244-1_4seq1.xml · nonDerivative · entry 3 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Jeffrey Brown Living Trust Disclosed balance after: 410 F2 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $125.57 to $125.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnotes 2 and 3 herein. F4 · ownership.nature: These shares are directly owned by Jeffrey Brown Living Trust, for which the reporting person is the sole trustee and sole beneficiary. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:02 UTC |
SCHLACKMAN SCOTTDirector
|
GrantCommon Stock | 7.906 | $138.78 | $1,097.19 |
DisclosureSEC source: 0001104659-22-088741 · tm2223137-6_4seq1.xml · nonDerivative · entry 1 SCHLACKMAN SCOTT · CIK 0001645617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,259.906 F1 · kind: Accrual of dividend equivalents in connection with deferred units held by the Reporting Person pursuant to the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). The dividend equivalents accrued when and as dividends were paid on Medifast common stock. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:02 UTC |
Xian MingDirector
|
GrantRestricted Stock Units (cash settled) · Derivative | 7.445 | $138.78 | $1,033.22 |
DisclosureSEC source: 0001104659-22-088740 · tm2223137-5_4seq1.xml · derivative · entry 1 Xian Ming · CIK 0001743879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,954.445 Underlying: Common Stock · 7.445 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (cash settled) is the economic equivalent of one share of Medifast's common stock. Restricted stock units become payable, in cash, following termination of the Reporting Person's service as a director. F2 · kind: Accrual of dividend equivalents in connection with deferred units held by the Reporting Person pursuant to the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). The dividend equivalents accrued when and as dividends were paid on Medifast common stock. F1 · derivative.exercise_date: Each restricted stock unit (cash settled) is the economic equivalent of one share of Medifast's common stock. Restricted stock units become payable, in cash, following termination of the Reporting Person's service as a director. F1 · derivative.expiration_date: Each restricted stock unit (cash settled) is the economic equivalent of one share of Medifast's common stock. Restricted stock units become payable, in cash, following termination of the Reporting Person's service as a director. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:02 UTC |
Hoer Michael A.Director
|
GrantCommon Stock | 7.681 | $138.78 | $1,065.97 |
DisclosureSEC source: 0001104659-22-088738 · tm2223137-4_4seq1.xml · nonDerivative · entry 1 Hoer Michael A. · CIK 0001743755 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,137.681 F1 · kind: Accrual of dividend equivalents in connection with deferred units held by the Reporting Person pursuant to the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). The dividend equivalents accrued when and as dividends were paid on Medifast common stock. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:01 UTC |
BROWN JEFFREY JDirector
|
GrantCommon Stock | 9.04 | $138.78 | $1,254.57 |
DisclosureSEC source: 0001104659-22-088736 · tm2223137-3_4seq1.xml · nonDerivative · entry 1 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,354.04 F1 · kind: Accrual of dividend equivalents in connection with deferred units held by the Reporting Person pursuant to the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). The dividend equivalents accrued when and as dividends were paid on Medifast common stock. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:01 UTC |
HALLQUIST CONSTANCE J.Director
|
GrantCommon Stock | 8.024 | $138.78 | $1,113.57 |
DisclosureSEC source: 0001104659-22-088735 · tm2223137-2_4seq1.xml · nonDerivative · entry 1 HALLQUIST CONSTANCE J. · CIK 0001645615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,882.024 F1 · kind: Accrual of dividend equivalents in connection with deferred units held by the Reporting Person pursuant to the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). The dividend equivalents accrued when and as dividends were paid on Medifast common stock. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 22:01 UTC |
Thomas Andrea BDirector
|
GrantCommon Stock | 7.788 | $138.78 | $1,080.82 |
DisclosureSEC source: 0001104659-22-088734 · tm2223137-1_4seq1.xml · nonDerivative · entry 1 Thomas Andrea B · CIK 0001779769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,013.788 F1 · kind: Accrual of dividend equivalents in connection with deferred units held by the Reporting Person pursuant to the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). The dividend equivalents accrued when and as dividends were paid on Medifast common stock. Read SEC document |
| August 04, 2022 Filed Aug 10, 2022 22:01 UTC |
BROWN JEFFREY JDirector
|
PurchaseCommon Stock | 399.162 | $146.01 | $58,283.40 |
DisclosureSEC source: 0001104659-22-088736 · tm2223137-3_4seq1.xml · nonDerivative · entry 2 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Brown Equity Partners, LLC Disclosed balance after: 35,937.85 F2 · kind: The shares were acquired by Brown Equity Partners, LLC, for which the reporting person is the managing member, pursuant to a broker-sponsored Dividend Reinvestment Plan. F3 · ownership.nature: These shares are directly owned by Brown Equity Partners, LLC, for which the reporting persons is the managing member. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 22:57 UTC |
Maloney James P.Chief Financial Officer
|
Tax withholdingCommon Stock | 115 | $174.44 | $20,060.60 |
DisclosureSEC source: 0001104659-22-082119 · tm2221679-1_4seq1.xml · nonDerivative · entry 1 Maloney James P. · CIK 0001715428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,944 Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:17 UTC |
Xian MingDirector
|
GrantRestricted Stock Units (cash settled) · Derivative | 1,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073172 · tm2219043-6_4seq1.xml · derivative · entry 1 Xian Ming · CIK 0001743879 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,947 Underlying: Common Stock · 1,317 shares Expires not disclosed F1 · derivative.exercise_price: Represents the contingent right to receive 1,317 shares of the Issuer's common stock or the cash equivalent in connection with the payment of the reporting person's annual director fees, which fees have been deferred under the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated) (the "Deferred Compensation Plan"). These shares are granted from the Issuer's 2012 Share Incentive Plan and will vest in full on June 16, 2023. The restricted stock units will become payable in cash upon or following the reporting person's termination of service as a director of the Issuer pursuant to the terms of the Deferred Compensation Plan. F1 · derivative.exercise_date: Represents the contingent right to receive 1,317 shares of the Issuer's common stock or the cash equivalent in connection with the payment of the reporting person's annual director fees, which fees have been deferred under the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated) (the "Deferred Compensation Plan"). These shares are granted from the Issuer's 2012 Share Incentive Plan and will vest in full on June 16, 2023. The restricted stock units will become payable in cash upon or following the reporting person's termination of service as a director of the Issuer pursuant to the terms of the Deferred Compensation Plan. F1 · derivative.expiration_date: Represents the contingent right to receive 1,317 shares of the Issuer's common stock or the cash equivalent in connection with the payment of the reporting person's annual director fees, which fees have been deferred under the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated) (the "Deferred Compensation Plan"). These shares are granted from the Issuer's 2012 Share Incentive Plan and will vest in full on June 16, 2023. The restricted stock units will become payable in cash upon or following the reporting person's termination of service as a director of the Issuer pursuant to the terms of the Deferred Compensation Plan. F2 · balance_after: Mr. Xian's beneficial ownership consists of 1,317 and 630 restricted stock units granted June 16, 2022 and June 3, 2021, respectively, all of which are deferred pursuant to the terms of the Deferred Compensation Plan. Prior grants of restricted stock units for Mr. Xian were settled in cash on their respective vesting dates. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:16 UTC |
SCHLACKMAN SCOTTDirector
|
GrantCommon Stock | 1,448 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073171 · tm2219043-5_4seq1.xml · nonDerivative · entry 1 SCHLACKMAN SCOTT · CIK 0001645617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,252 F1 · shares: Represents the right to receive 1,448 shares of the Issuer's common stock in connection with the payment of the reporting person's annual director fees, which fees have been deferred under the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). These shares are granted from the Issuer's 2012 Share Incentive Plan and will vest in full on June 16, 2023. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:16 UTC |
BROWN JEFFREY JDirector
|
GrantCommon Stock | 1,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073169 · tm2219043-3_4seq1.xml · nonDerivative · entry 1 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,345 F1 · shares: Represents the right to receive 1,580 shares of the Issuer's common stock in connection with the payment of the reporting person's annual director fees, which fees have been deferred under the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). These shares are granted from the Issuer's 2012 Share Incentive Plan and will vest in full on June 16, 2023. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:16 UTC |
Hoer Michael A.Director
|
GrantCommon Stock | 1,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073170 · tm2219043-4_4seq1.xml · nonDerivative · entry 1 Hoer Michael A. · CIK 0001743755 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,130 F1 · shares: Represents the right to receive 1,350 shares of the Issuer's common stock in connection with the payment of the reporting person's annual director fees, which fees have been deferred under the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). These shares are granted from the Issuer's 2012 Share Incentive Plan and will vest in full on June 16, 2023. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:15 UTC |
HALLQUIST CONSTANCE J.Director
|
GrantCommon Stock | 1,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073168 · tm2219043-2_4seq1.xml · nonDerivative · entry 1 HALLQUIST CONSTANCE J. · CIK 0001645615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,874 F1 · shares: Represents the right to receive 1,432 shares of the Issuer's common stock in connection with the payment of the reporting person's annual director fees, which fees have been deferred under the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). These shares are granted from the Issuer's 2012 Share Incentive Plan and will vest in full on June 16, 2023. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:15 UTC |
Thomas Andrea BDirector
|
GrantCommon Stock | 1,366 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-073167 · tm2219043-1_4seq1.xml · nonDerivative · entry 1 Thomas Andrea B · CIK 0001779769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,006 F1 · shares: Represents the right to receive 1,366 shares of the Issuer's common stock in connection with the payment of the reporting person's annual director fees, which fees have been deferred under the Medifast, Inc. Director's Deferred Compensation Plan (Amended and Restated). These shares are granted from the Issuer's 2012 Share Incentive Plan and will vest in full on June 16, 2023. Read SEC document |
| May 05, 2022 Filed May 12, 2022 00:02 UTC |
BROWN JEFFREY JDirector
|
PurchaseCommon Stock | 315.236 | $183.25 | $57,767.00 |
DisclosureSEC source: 0001104659-22-058940 · tm2215276d2_4.xml · nonDerivative · entry 1 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Brown Equity Partners, LLC Disclosed balance after: 35,538.688 F1 · kind: The shares were acquired by Brown Equity Partners, LLC, for which the reporting person is the managing member, pursuant to a broker-sponsored Dividend Reinvestment Plan. F2 · ownership.nature: These shares are directly owned by Brown Equity Partners, LLC, for which the reporting person is the managing member. Read SEC document |
| May 05, 2022 Filed May 12, 2022 00:01 UTC |
Chard Daniel RDirector · Chairman & CEO
|
PurchaseCommon Stock | 431.078 | $183.25 | $78,995.04 |
DisclosureSEC source: 0001104659-22-058937 · tm2215276d1_4.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · The Dan and Allyson Family Irrevocable Trust Disclosed balance after: 108,598.352 F1 · kind: The shares were acquired by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is Settlor of the Trust and Investment Trustee, pursuant to a broker-sponsored Dividend Reinvestment Plan. F2 · ownership.nature: These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. Read SEC document |
| March 21, 2022 Filed Apr 22, 2022 00:59 UTC |
Chard Daniel RDirector · Chairman & CEO
|
GiftCommon Stock | 953 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-048540 · tm2213324d2_4.xml · nonDerivative · entry 5 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · The Dan and Allyson Family Irrevocable Trust Disclosed balance after: 108,167.274 F3 · kind: The reporting person transferred these shares to The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. F2 · ownership.nature: These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. Read SEC document |
| March 21, 2022 Filed Apr 22, 2022 00:59 UTC |
Chard Daniel RDirector · Chairman & CEO
|
GiftCommon Stock | 953 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-048540 · tm2213324d2_4.xml · nonDerivative · entry 4 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,933 F3 · kind: The reporting person transferred these shares to The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 22:58 UTC |
Maloney James P.Chief Financial Officer
|
Tax withholdingCommon Stock | 75 | $180.52 | $13,539.00 |
DisclosureSEC source: 0001104659-22-036229 · tm2210070-3_4seq1.xml · nonDerivative · entry 2 Maloney James P. · CIK 0001715428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,059 Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 22:57 UTC |
Chard Daniel RDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 878 | $180.52 | $158,496.56 |
DisclosureSEC source: 0001104659-22-036227 · tm2210070-1_4seq1.xml · nonDerivative · entry 2 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,261 Read SEC document |
| March 16, 2022 Filed Mar 21, 2022 22:58 UTC |
Maloney James P.Chief Financial Officer
|
GrantCommon Stock | 1,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-036229 · tm2210070-3_4seq1.xml · nonDerivative · entry 1 Maloney James P. · CIK 0001715428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,134 F1 · shares: Represents a grant of restricted stock units issued to the reporting person under the 2012 Share Incentive Plan that will vest in three equal annual installments beginning on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock Read SEC document |
| March 16, 2022 Filed Mar 21, 2022 22:57 UTC |
Chard Daniel RDirector · Chairman & CEO
|
GrantCommon Stock | 8,509 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-036227 · tm2210070-1_4seq1.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,139 F1 · shares: Represents a grant of restricted stock units issued to the reporting person under the 2012 Share Incentive Plan that will vest in three equal annual installments beginning on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 16, 2022 Filed Mar 21, 2022 22:57 UTC |
MacKenzie Jonathan BarrettVP, Finance & CAO
|
GrantCommon Stock | 548 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-036228 · tm2210070-2_4seq1.xml · nonDerivative · entry 1 MacKenzie Jonathan Barrett · CIK 0001883230 · VP, Finance & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657 F1 · shares: Represents a grant of restricted stock units issued to the reporting person under the 2012 Share Incentive Plan that will vest in three equal annual installments beginning on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 23:36 UTC |
Thomas Andrea BDirector
|
SaleCommon Stock | 1,150 | $174.31 | $200,456.50 |
DisclosureSEC source: 0001104659-22-033486 · tm229251-1_4seq1.xml · nonDerivative · entry 1 Thomas Andrea B · CIK 0001779769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,640 Read SEC document |
| February 23, 2022 Filed Apr 22, 2022 00:59 UTC |
Chard Daniel RDirector · Chairman & CEO
|
GiftCommon Stock | 3,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-048540 · tm2213324d2_4.xml · nonDerivative · entry 3 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · The Dan and Allyson Family Irrevocable Trust Disclosed balance after: 107,214.274 F3 · kind: The reporting person transferred these shares to The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. F2 · ownership.nature: These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. Read SEC document |
| February 23, 2022 Filed Apr 22, 2022 00:59 UTC |
Chard Daniel RDirector · Chairman & CEO
|
GiftCommon Stock | 3,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-048540 · tm2213324d2_4.xml · nonDerivative · entry 2 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,886 F3 · kind: The reporting person transferred these shares to The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:06 UTC |
Chard Daniel RDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 1,282 | $177.06 | $226,990.92 |
DisclosureSEC source: 0001104659-22-026864 · tm227685-1_4seq1.xml · nonDerivative · entry 2 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,630 F3 · date: These shares vested on February 20, 2022, which fell on a weekend. The settlement date of this vesting and subsequent withholding fell on the following business day, February 22, 2022. F2 · price: Pursuant to the terms of the Issuer's Amended and Restated 2012 Share Incentive Plan, the price was the closing sales price for the most recent trading day prior to the vesting date. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:06 UTC |
Chard Daniel RDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 1,804 | $177.06 | $319,416.24 |
DisclosureSEC source: 0001104659-22-026864 · tm227685-1_4seq1.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,912 F1 · date: These shares vested on February 19, 2022, which fell on a weekend. The settlement date of this vesting and subsequent withholding fell on the following business day, February 22, 2022. F2 · price: Pursuant to the terms of the Issuer's Amended and Restated 2012 Share Incentive Plan, the price was the closing sales price for the most recent trading day prior to the vesting date. Read SEC document |
| February 04, 2022 Filed Apr 22, 2022 00:59 UTC |
Chard Daniel RDirector · Chairman & CEO
|
PurchaseCommon Stock | 690.274 | $186.40 | $128,667.07 |
DisclosureSEC source: 0001104659-22-048540 · tm2213324d2_4.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · The Dan and Allyson Family Irrevocable Trust Disclosed balance after: 103,839.274 F1 · kind: The shares were acquired by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is Settlor of the Trust and Investment Trustee, pursuant to a broker-sponsored Dividend Reinvestment Plan. F2 · ownership.nature: These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. Read SEC document |
| February 04, 2022 Filed Apr 22, 2022 00:58 UTC |
BROWN JEFFREY JDirector
|
PurchaseCommon Stock | 266.306 | $186.40 | $49,639.44 |
DisclosureSEC source: 0001104659-22-048539 · tm2213324d1_4.xml · nonDerivative · entry 1 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Brown Equity Partners, LLC Disclosed balance after: 35,223.452 F1 · kind: The shares were acquired by Brown Equity Partners, LLC, for which the reporting person is the managing member, pursuant to a broker-sponsored Dividend Reinvestment Plan. F2 · ownership.nature: These shares are directly owned by Brown Equity Partners, LLC, for which the reporting person is the managing member. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:05 UTC |
Chard Daniel RDirector · Chairman & CEO
|
GiftCommon Stock | 12,539 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-000895 · tm221539-1_4seq1.xml · nonDerivative · entry 4 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · The Dan and Allyson Family Irrevocable Trust Disclosed balance after: 103,149 F2 · kind: The reporting person transferred these shares to The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. F3 · ownership.nature: These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:05 UTC |
Chard Daniel RDirector · Chairman & CEO
|
GiftCommon Stock | 12,539 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-000895 · tm221539-1_4seq1.xml · nonDerivative · entry 3 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,716 F2 · kind: The reporting person transferred these shares to The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:05 UTC |
Chard Daniel RDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 11,533 | $209.43 | $2,415,356.19 |
DisclosureSEC source: 0001104659-22-000895 · tm221539-1_4seq1.xml · nonDerivative · entry 2 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,255 Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 21:05 UTC |
Chard Daniel RDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 24,072 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-000895 · tm221539-1_4seq1.xml · nonDerivative · entry 1 Chard Daniel R · CIK 0001289557 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: 12,036 Performance Stock Units were granted on February 20, 2019, and vested on December 31, 2021 and converted into common stock on a two-for-one basis due to the achievement of certain performance factors. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 01:10 UTC |
BYRNES KEVIN GDirector
|
Exercise / conversionStock Options · Derivative | 5,000 | $0.00 Strike: $27.68 | $0.00 |
DisclosureSEC source: 0001104659-21-139471 · tm2133024-1_4seq1.xml · derivative · entry 7 BYRNES KEVIN G · CIK 0001224725 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options vested in three equal annual installments beginning on February 4, 2017. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 01:10 UTC |
BYRNES KEVIN GDirector
|
Exercise / conversionStock Options · Derivative | 5,000 | $0.00 Strike: $31.55 | $0.00 |
DisclosureSEC source: 0001104659-21-139471 · tm2133024-1_4seq1.xml · derivative · entry 6 BYRNES KEVIN G · CIK 0001224725 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options vested in three equal annual installments beginning on February 17, 2016. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 01:10 UTC |
BYRNES KEVIN GDirector
|
Exercise / conversionStock Options · Derivative | 2,917 | $0.00 Strike: $26.52 | $0.00 |
DisclosureSEC source: 0001104659-21-139471 · tm2133024-1_4seq1.xml · derivative · entry 5 BYRNES KEVIN G · CIK 0001224725 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,917 shares Expires 2024-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options vested in three equal annual installments beginning on February 5, 2015. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 01:10 UTC |
BYRNES KEVIN GDirector
|
Tax withholdingCommon Stock | 6,149 | $228.45 | $1,404,739.05 |
DisclosureSEC source: 0001104659-21-139471 · tm2133024-1_4seq1.xml · nonDerivative · entry 4 BYRNES KEVIN G · CIK 0001224725 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,922 F1 · shares: Represents a withholding of 6,149 shares of the Issuer's common stock to satisfy the exercise price and the tax obligation in connection with the exercise of certain stock options. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 01:10 UTC |
BYRNES KEVIN GDirector
|
Exercise / conversionCommon Stock | 5,000 | $27.68 | $138,400.00 |
DisclosureSEC source: 0001104659-21-139471 · tm2133024-1_4seq1.xml · nonDerivative · entry 3 BYRNES KEVIN G · CIK 0001224725 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 01:10 UTC |
BYRNES KEVIN GDirector
|
Exercise / conversionCommon Stock | 5,000 | $31.55 | $157,750.00 |
DisclosureSEC source: 0001104659-21-139471 · tm2133024-1_4seq1.xml · nonDerivative · entry 2 BYRNES KEVIN G · CIK 0001224725 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 16, 2021 01:10 UTC |
BYRNES KEVIN GDirector
|
Exercise / conversionCommon Stock | 2,917 | $26.52 | $77,358.84 |
DisclosureSEC source: 0001104659-21-139471 · tm2133024-1_4seq1.xml · nonDerivative · entry 1 BYRNES KEVIN G · CIK 0001224725 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2021 Filed Nov 11, 2021 02:17 UTC |
BROWN JEFFREY JDirector
|
PurchaseCommon Stock | 600 | $235.28 | $141,168.00 |
DisclosureSEC source: 0001104659-21-137193 · tm2132609d1_4.xml · nonDerivative · entry 10 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Brown Equity Partners, LLC Disclosed balance after: 34,957.146 F10 · price: This transaction was executed in multiple trades at prices ranging from $235.00 USD to $235.71 USD; the price reported above reflects the weighted average sale price. F11 · ownership.nature: These shares are directly owned by Brown Equity Partners, LLC, for which the reporting person is the managing member. Read SEC document |
| November 08, 2021 Filed Nov 11, 2021 02:17 UTC |
BROWN JEFFREY JDirector
|
PurchaseCommon Stock | 1,000 | $234.52 | $234,520.00 |
DisclosureSEC source: 0001104659-21-137193 · tm2132609d1_4.xml · nonDerivative · entry 9 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Brown Equity Partners, LLC Disclosed balance after: 34,357.146 F9 · price: This transaction was executed in multiple trades at prices ranging from $234.11 USD to $234.99 USD; the price reported above reflects the weighted average sale price. F11 · ownership.nature: These shares are directly owned by Brown Equity Partners, LLC, for which the reporting person is the managing member. Read SEC document |
| November 08, 2021 Filed Nov 11, 2021 02:17 UTC |
BROWN JEFFREY JDirector
|
PurchaseCommon Stock | 593 | $233.68 | $138,572.24 |
DisclosureSEC source: 0001104659-21-137193 · tm2132609d1_4.xml · nonDerivative · entry 8 BROWN JEFFREY J · CIK 0001245377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Brown Equity Partners, LLC Disclosed balance after: 33,357.146 F8 · price: This transaction was executed in multiple trades at prices ranging from $233.12 USD to $233.96 USD; the price reported above reflects the weighted average sale price. F11 · ownership.nature: These shares are directly owned by Brown Equity Partners, LLC, for which the reporting person is the managing member. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.